SCHEMBL15337315

SCHEMBL15337315

COc1cccc(C(=O)CC2(O)C(=O)Nc3c(Cl)ccc(Cl)c32)c1

nearest known ligand 0.77

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FLI1 Q01543 5/20 0.77
EWSR1 Q01844 5/20 0.77
ERG P11308 1/20 0.77
ETV1 P50549 1/20 0.77
CDYL Q9Y232 4/20 0.63
CBX7 O95931 3/20 0.63
ALDH1A1 P00352 6/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
HTT P42858 1/20 0.53
CDYL2 Q8N8U2 3/20 0.48
CDY1; CDY1B Q9Y6F8 2/20 0.48
MMP2 P08253 2/20 0.47
MMP9 P14780 2/20 0.47
MMP8 P22894 2/20 0.47
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15337311 0.91 FLI1 (0.80) FLI1EWSR1ERGETV1CDYL
SCHEMBL19829782 0.87 FLI1 (1.00) FLI1EWSR1ERGETV1CDYL
SCHEMBL29399443 0.87 FLI1 (1.00) FLI1EWSR1ERGETV1CDYL
SCHEMBL3486735 0.87 FLI1 (1.00) FLI1EWSR1ERGETV1CDYL
SCHEMBL19829781 0.87 FLI1 (1.00) FLI1EWSR1ERGETV1CDYL
SCHEMBL13253328 0.85 FLI1 (0.65) FLI1EWSR1ERGETV1CDYL
SCHEMBL16489838 0.84 FLI1 (0.71) FLI1EWSR1ERGETV1CDYL
SCHEMBL3486249 0.84 FLI1 (0.73) FLI1EWSR1ERGETV1CDYL
SCHEMBL15337313 0.84 FLI1 (0.73) FLI1EWSR1ERGETV1CDYL
SCHEMBL13253330 0.83 FLI1 (0.71) FLI1EWSR1ERGETV1CDYL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9714222-B2 Methods and compositions for treating Ewings sarcoma family of tumors GEORGETOWN UNIVERSITY (US) 2017-07-25 US disclosed
US-9714222-B2 Methods and compositions for treating Ewings sarcoma family of tumors GEORGETOWN UNIVERSITY (US) 2017-07-25 US disclosed
US-20170157089-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER NIH - DEITR 2017-06-08 US disclosed
US-20170157089-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER NIH - DEITR 2017-06-08 US disclosed
US-9511050-B2 Methods and compositions for treating cancer GEORGETOWN UNIVERSITY (US) 2016-12-06 US disclosed
US-9511050-B2 Methods and compositions for treating cancer GEORGETOWN UNIVERSITY (US) 2016-12-06 US disclosed
US-20160263086-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER GEORGETOWN UNIVERSITY (US) 2016-09-15 US disclosed
US-20160263086-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER GEORGETOWN UNIVERSITY (US) 2016-09-15 US disclosed
US-20160159741-A1 METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS GEORGETOWN UNIVERSITY 2016-06-09 US disclosed
US-20160159741-A1 METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS GEORGETOWN UNIVERSITY 2016-06-09 US disclosed
US-9290449-B2 Methods and compositions for treating Ewings sarcoma family of tumors GEORGETOWN UNIVERSITY (US) 2016-03-22 US disclosed
US-9290449-B2 Methods and compositions for treating Ewings sarcoma family of tumors GEORGETOWN UNIVERSITY (US) 2016-03-22 US disclosed
US-20150051260-A1 METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS GEORGETOWN UNIVERSITY (US) 2015-02-19 US disclosed
US-20150051260-A1 METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS GEORGETOWN UNIVERSITY (US) 2015-02-19 US disclosed
WO-2013155341-A1 METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS GEORGETOWN UNIVERSITY (US) 2013-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150051260-A1 METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS EWSR1, FLI1, CDC73 FLI1 2/4885EWSR1 1/4885ERG 81/4885
US-20170157089-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER MGMT, TP53, KRAS FLI1 527/4885EWSR1 17/4885ERG 530/4885
US-20160159741-A1 METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS EWSR1, FLI1, CDC73 FLI1 2/4885EWSR1 1/4885ERG 81/4885
US-20160263086-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER MGMT, TP53, KRAS FLI1 527/4885EWSR1 17/4885ERG 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.